You have Guest access.
Log In
Steven G. Elliott, Mary Ann Foote and Graham Molineux
I-XVIII
Front matter
3-74
Part 1 / Background
3-18
Erythropoiesis: an overview
19-40
Regulation of endogenous erythropoietin production
41-60
Biology of erythropoietin
61-74
Erythropoiesis—genetic abnormalities
77-140
Part 2 / Erythropoiesis-stimulating agents
77-85
Studies of erythropoiesis and the discovery and cloning of recombinant human erythropoietin
87-104
Commercial production of recombinant erythropoietins
105-114
Biosimilar epoetins
115-140
New molecules and formulations
143-196
Part 3 / Erythropoietin receptor
143-153
Structural basis for the signal transduction of erythropoietin
155-174
Intracellular signaling by the erythropoietin receptor
175-196
Mechanism of erythropoietin receptor activation
199-317
Part 4 / Clinical utility
199-223
Pharmacokinetics of erythropoiesis-stimulating agents
225-248
Use of erythropoietic stimulating agents in the setting of renal disease
249-278
Abuse of recombinant erythropoietins and blood products by athletes
279-298
Role and regulation of iron metabolism in erythropoiesis and disease
299-317
Nonhematopoietic effects of erythropoiesis-stimulating agents
319-328
Back matter
This page requires script.
Frequently asked questions General info on journals and books Send us your feedback Impressum Contact us
© Springer, Part of Springer Science+Business Media Privacy, Disclaimer, Terms & Conditions, and Copyright Info